Published online before print October 25, 2007, doi: 10.1161/CIRCRESAHA.107.155028
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 27, 2007
Revised on September 5, 2007
Accepted on October 15, 2007
Diabetes-Induced Coronary Vascular Dysfunction Involves Increased Arginase Activity
Maritza J. Romero ;
From the Department of Pharmacology & Toxicology (M.J.R., D.H.P., H.E.T., A.B.E.-R., R.W.C.), Vascular Biology Center (M.L., M.B., R.B.C.), and Department of Cellular Biology and Anatomy (R.B.C.), Medical College of Georgia, Augusta.
* To whom correspondence should be addressed. E-mail: wcaldwel{at}mail.mcg.edu.
Increases in arginase activity have been reported in a variety of disease conditions characterized by vascular dysfunction. Arginase competes with NO synthase (NOS) for their common substrate arginine, suggesting a cause and effect relationship. We tested this concept by experiments with streptozotocin diabetic rats and high glucose (HG)-treated bovine coronary endothelial cells (BCECs). Our studies showed that diabetes-induced impairment of vasorelaxation to acetylcholine was correlated with increases in reactive oxygen species and arginase activity and arginase I expression in aorta and liver. Treatment of diabetic rats with simvastatin (5 mg/kg per day, subcutaneously) or L-citrulline (50 mg/kg per day, orally) blunted these effects. Acute treatment of diabetic coronary arteries with arginase inhibitors also reversed the impaired vasodilation to acetylcholine. Treatment of BCECs with HG (25 mmol/L, 24 hours) also increased arginase activity. This effect was blocked by treatment with simvastatin (0.1 µmol/L), the Rho kinase inhibitor Y-27632 (10 µmol/L), or L-citrulline (1 mmol/L). Superoxide and active RhoA levels also were elevated in HG-treated BCECs. Furthermore, HG significantly diminished NO production in BCECs. Transfection of BCECs with arginase I small interfering RNA prevented the rise in arginase activity in HG-treated cells and normalized NO production, suggesting a role for arginase I in reduced NO production with HG. These results indicate that increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing L-arginine availability to NOS.
Key words: arginine • coronary arteries • diabetes • endothelial nitric oxide synthase • oxidative stress • vascular endothelial function • vasodilation
Related Article:
- Sweet and Sour: Unraveling Diabetic Vascular Disease
- Thomas F. Luscher and Jan Steffel
Circ. Res. 2008 102: 9-11.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
 |
|
 |
|
  J. H. Kim, L. J. Bugaj, Y. J. Oh, T. J. Bivalacqua, S. Ryoo, K. G. Soucy, L. Santhanam, A. Webb, A. Camara, G. Sikka, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats J Appl Physiol, October 1, 2009; 107(4): 1249 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Nuno, J. S. Harrod, and K. G. Lamping Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1469 - H1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jung, A. T. Gonon, P.-O. Sjoquist, J. O. Lundberg, and J. Pernow Arginase inhibition mediates cardioprotection during ischaemia-reperfusion Cardiovasc Res, September 18, 2009; (2009) cvp303v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, B. Baban, M. Rojas, S. Tofigh, S. K. Virmani, C. Patel, M. A. Behzadian, M. J. Romero, R. W. Caldwell, and R. B. Caldwell Arginase Activity Mediates Retinal Inflammation in Endotoxin-Induced Uveitis Am. J. Pathol., August 1, 2009; 175(2): 891 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Pieper, I. A. Ionova, B. C. Cooley, R. Q. Migrino, A. K. Khanna, J. Whitsett, and J. Vasquez-Vivar Sepiapterin Decreases Acute Rejection and Apoptosis in Cardiac Transplants Independently of Changes in Nitric Oxide and Inducible Nitric-Oxide Synthase Dimerization J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 890 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cignarella, C. Bolego, V. Pelosi, C. Meda, A. Krust, C. Pinna, R. M. Gaion, E. Vegeto, and A. Maggi Distinct Roles of Estrogen Receptor-{alpha} and {beta} in the Modulation of Vascular Inducible Nitric-Oxide Synthase in Diabetes J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 174 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Santhanam, D. W. Christianson, D. Nyhan, and D. E. Berkowitz Arginase and vascular aging J Appl Physiol, November 1, 2008; 105(5): 1632 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Vanhoutte Arginine and Arginase: Endothelial NO Synthase Double Crossed? Circ. Res., April 25, 2008; 102(8): 866 - 868. [Full Text] [PDF]
|
|
|
|
|
|
S. Ryoo, G. Gupta, A. Benjo, H. K. Lim, A. Camara, G. Sikka, H. K. Lim, J. Sohi, L. Santhanam, K. Soucy, et al. Endothelial Arginase II: A Novel Target for the Treatment of Atherosclerosis Circ. Res., April 25, 2008; 102(8): 923 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and J. Steffel Sweet and Sour: Unraveling Diabetic Vascular Disease Circ. Res., January 4, 2008; 102(1): 9 - 11. [Full Text] [PDF]
|
|